CC
ALXN

ClearArc Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

ClearArc Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$255K Sell
2,361
-1,021
-30% -$109K 0.1% 240
2019
Q3 		$331K Buy
3,382
+53
+2% +$5.97K 0.1% 245
2019
Q2 		$436K Sell
3,329
-400
-11% -$51.6K 0.13% 190
2019
Q1 		$504K Sell
3,729
-100
-3% -$12.4K 0.14% 180
2018
Q4 		$373K Sell
3,829
-1,924
-33% -$227K 0.11% 211
2018
Q3 		$800K Buy
5,753
+79
+1% +$9.91K 0.1% 193
2018
Q2 		$704K Sell
5,674
-6
-0.1% -$701 0.1% 203
2018
Q1 		$633K Sell
5,680
-24
-0.4% -$2.87K 0.1% 220
2017
Q4 		$682K Sell
5,704
-17
-0.3% -$2.07K 0.09% 216
2017
Q3 		$803K Buy
5,721
+201
+4% +$27.3K 0.12% 183
2017
Q2 		$672K Buy
5,520
+25
+0.5% +$2.91K 0.11% 200
2017
Q1 		$666K Buy
5,495
+53
+1% +$6.83K 0.11% 196
2016
Q4 		$666K Sell
5,442
-61
-1% -$7.46K 0.12% 187
2016
Q3 		$674K Buy
5,503
+75
+1% +$9.65K 0.13% 182
2016
Q2 		$634K Sell
5,428
-77
-1% -$10.9K 0.12% 187
2016
Q1 		$766K Sell
5,505
-7
-0.1% -$1.03K 0.16% 155
2015
Q4 		$1.05M Buy
5,512
+18
+0.3% +$3.14K 0.22% 123
2015
Q3 		$859K Sell
5,494
-49
-0.9% -$8.94K 0.18% 156
2015
Q2 		$1M Buy
5,543
+1,173
+27% +$202K 0.18% 146
2015
Q1 		$757K Buy
4,370
+125
+3% +$22.6K 0.16% 172
2014
Q4 		$785K Buy
4,245
+147
+4% +$27.2K 0.16% 170
2014
Q3 		$680K Buy
4,098
+110
+3% +$18.1K 0.15% 175
2014
Q2 		$623K Buy
3,988
+71
+2% +$11.2K 0.14% 186
2014
Q1 		$596K Buy
3,917
+23
+0.6% +$3.66K 0.15% 183
2013
Q4 		$517K Buy
3,894
+123
+3% +$14.8K 0.13% 190
2013
Q3 		$438K Buy
3,771
+30
+0.8% +$3.29K 0.12% 199
2013
Q2 		$345K Buy
+3,741
New +$361K 0.09% 241

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearArc Capital's ALXN Position: Q4 2019 in Review

ClearArc Capital reduced its Alexion Pharmaceuticals (ALXN) stake by 30% in Q4 2019, selling an estimated $109K and leaving 2,361 shares worth $255K. The position accounts for 0.1% of the portfolio, ranked #240.

ClearArc Capital first reported a position in ALXN in Q2 2013 and has held it in 27 quarters since. The position peaked at $1.05M in Q4 2015. 668 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • ClearArc Capital held 2,361 shares of Alexion Pharmaceuticals worth $255K as of Q4 2019.
  • ClearArc Capital sold 1,021 Alexion Pharmaceuticals shares in Q4 2019, an estimated $109K.
  • Alexion Pharmaceuticals made up 0.1% of ClearArc Capital's portfolio in Q4 2019, its #240 holding.
  • ClearArc Capital first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • ClearArc Capital's Alexion Pharmaceuticals position peaked at $1.05M in Q4 2015.
  • 668 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on ClearArc Capital's 13F filing for Q4 2019, filed 14 Feb 2020.